Listen
PROCORALAN
-
Opinions on drugs -
Posted on
May 29 2006
- Updated on
Jan 15 2009
Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals
-
Clinical Benefit
| Substantial |
The actual medical benefit of this proprietary drug in this indication is significant. |
Clinical Added Value
| moderate |
The Transparency Committee considers that PROCORALAN provides a moderate improvement in actual benefit (IAB III) in patients with chronic stable angina with a contraindication or intolerance to beta-blockers and with asymptomatic left ventricular dysfunction (LVEF < 45 %) contraindicating the use of heart rate-decreasing calcium antagonists. |
Contact Us
Évaluation des médicaments
